Boundary and scope: the dilemma of Chinese herbal medicine practice in the US concerning incidents during the COVID-19 pandemic

Abstract

[Abstract]: During COVID-19 pandemic, Chinese herbal medicine practices in the United States face challenges for Chinese herbal products application. The FDA has issued at least seven warning letters for alleging these products help to prevent, treat, mitigate, diagnose, or cure coronavirus disease 2019. Although Chinese herbal medicine has been imported to America for about two hundred years, the Chinese herbal products are categorized as dietary supplements and Chinese herbal medicine practices have limited scope and larger boundaries, which push the Unites States with Chinese herbal medicine practices far more behind. A CLAP (compliance, legislation, adaptation, and promotion) action plan is proposed to advance Chinese herbal medicine development in America.

Keywords

• Chinese Herbal Medicine
• Dietary Supplement
• Dilemma
• COVID-19
• United States